Extended Postoperative Oral Tranexamic Acid in Knee Replacement

Knee Osteoarthritis Clinical Trial

Official title:

Extended Postoperative Tranexamic Acid Use in Primary Total Knee Arthroplasty: A Prospective, Randomized Controlled Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05099276
• Other study ID #: 21-08313-FB
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: December 7, 2021
• Est. completion date: June 1, 2024

Study information

• Verified date: March 2024
• Source: Campbell Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A comparison of outcomes between use of oral tranexamic acid as compared to oral placebo in the first days after total knee replacement will be made to determine impact on clinical indications and patient reported outcomes.

Description:

Significant blood loss occurs during total knee arthroplasty (TKA) which can lead to adverse outcomes including need for blood transfusion as well as increased local tissue swelling and ecchymosis which can inhibit post-operative recovery. Tranexamic acid (TXA), an inhibitor of fibrinolysis, has been shown to be a safe and effective drug for reducing blood loss during and after TKA. The use of TXA intraoperatively has been associated with higher postoperative hemoglobin levels and a reduction in postoperative blood transfusion rates. Administration of TXA in TKA has also been associated with improved clinical outcome measures including decreased rate of periprosthetic joint infection, decreased length of stay, and increased postoperative range of motion and early ambulation distances. However, there remains a wide variance in the route of administration, dosage, and timing of TXA use among treatment protocols in TKA. Previous studies have evaluated outcomes with the addition of post-operative TXA dosing to standard pre-operative and intra-operative intravenous (IV) doses. This study will investigate patient outcomes following a standardized post-operative oral TXA protocol as compared to oral placebo for three doses over day of surgery, postop day one and postop day two after TKA.

Following written consent documentation, Subjects will be randomized and blinded to randomization assignment until completion of study to either the oral TXA group or oral placebo group. The study medication will be distributed with the Subject's name with instructions for use in the post-anesthesia unit (PACU). The first dose will be administered in PACU with subsequent doses to be taken at home on postop day one and postop day two. TKA will be completed in an ambulatory surgery center with discharge same day of surgery to home.

Outcome measures include: Hemoglobin, visual analog score, KOOS Jr (Knee injury and osteoarthritis outcome score), range of motion, and incidence of treatment-emergent adverse event at postoperative (POD) day 3, POD week 2, POD week 6, and POD week 12. KOOS Jr. will be collected at one year post-op.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 46
• Est. completion date: June 1, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Primary total knee replacement in ambulatory setting

• Willing to participate

• Physical therapy on site at Campbell Clinic Wolf River

• Fluent in oral and written English

Exclusion Criteria:

• Unwilling to participate

• Revision total knee replacement

• Preoperative use of anticoagulants other than 81 mg aspirin

• Previous history of thromboembolic event

• Previous history of cancer other than non-melanoma skin cancers

Related Conditions & MeSH terms

• Blood Loss
• Knee Osteoarthritis
• Pain, Postoperative

Intervention

Drug:
• Tranexamic Acid Pill
1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two
• Placebo
Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two

Locations

Country	Name	City	State
United States	Campbell Clinic	Germantown	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Campbell Clinic

Country where clinical trial is conducted

United States, 

References & Publications (13)

Drain NP, Gobao VC, Bertolini DM, Smith C, Shah NB, Rothenberger SD, Dombrowski ME, O'Malley MJ, Klatt BA, Hamlin BR, Urish KL. Administration of Tranexamic Acid Improves Long-Term Outcomes in Total Knee Arthroplasty. J Arthroplasty. 2020 Jun;35(6S):S201- — View Citation

Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Shores P, Mullen K, Bini SA, Clarke HD, Schemitsch E, Johnson RL, Memtsoudis SG, Sayeed SA, Sah AP, Della Valle CJ. The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis. J Arthroplasty. 2018 Oct;33(10):3070-3082.e1. doi: 10.1016/j.arth.2018.03.031. Epub 2018 Mar 22. — View Citation

Grosso MJ, Trofa DP, Danoff JR, Hickernell TR, Murtaugh T, Lakra A, Geller JA. Tranexamic acid increases early perioperative functional outcomes after total knee arthroplasty. Arthroplast Today. 2017 Jun 29;4(1):74-77. doi: 10.1016/j.artd.2017.05.009. eCo — View Citation

Kim JK, Park JY, Lee DY, Ro DH, Han HS, Lee MC. Optimal dose of topical tranexamic acid considering efficacy and safety in total knee arthroplasty: a randomized controlled study. Knee Surg Sports Traumatol Arthrosc. 2021 Oct;29(10):3409-3417. doi: 10.1007 — View Citation

Lei Y, Xie J, Huang Q, Huang W, Pei F. Additional benefits of multiple-dose tranexamic acid to anti-fibrinolysis and anti-inflammation in total knee arthroplasty: a randomized controlled trial. Arch Orthop Trauma Surg. 2020 Aug;140(8):1087-1095. doi: 10.1 — View Citation

Luo ZY, Wang HY, Wang D, Zhou K, Pei FX, Zhou ZK. Oral vs Intravenous vs Topical Tranexamic Acid in Primary Hip Arthroplasty: A Prospective, Randomized, Double-Blind, Controlled Study. J Arthroplasty. 2018 Mar;33(3):786-793. doi: 10.1016/j.arth.2017.09.06 — View Citation

Pavenski K, Ward SE, Hare GMT, Freedman J, Pulendrarajah R, Pirani RA, Sheppard N, Vance C, White A, Lo N, Waddell JP, Ho A, Schemitsch EH, Kataoka M, Bogoch ER, Saini K, David Mazer C, Baker JE. A rationale for universal tranexamic acid in major joint ar — View Citation

Prasad N, Padmanabhan V, Mullaji A. Blood loss in total knee arthroplasty: an analysis of risk factors. Int Orthop. 2007 Feb;31(1):39-44. doi: 10.1007/s00264-006-0096-9. Epub 2006 Mar 28. — View Citation

Rutherford RW, Jennings JM, Dennis DA. Enhancing Recovery After Total Knee Arthroplasty. Orthop Clin North Am. 2017 Oct;48(4):391-400. doi: 10.1016/j.ocl.2017.05.002. Epub 2017 Aug 8. — View Citation

Torkaman A, Rostami A, Sarshar MR, Akbari Aghdam H, Motaghi P, Yazdi H. The Efficacy of Intravenous Versus Topical Use of Tranexamic Acid in Reducing Blood Loss after Primary Total Knee Arthroplasty: A Randomized Clinical Trial. Arch Bone Jt Surg. 2020 Ma — View Citation

Wang D, Wang HY, Luo ZY, Meng WK, Pei FX, Li Q, Zhou ZK, Zeng WN. Blood-conserving efficacy of multiple doses of oral tranexamic acid associated with an enhanced-recovery programme in primary total knee arthroplasty: a randomized controlled trial. Bone Jo — View Citation

Wang HY, Wang L, Luo ZY, Wang D, Tang X, Zhou ZK, Pei FX. Intravenous and subsequent long-term oral tranexamic acid in enhanced-recovery primary total knee arthroplasty without the application of a tourniquet: a randomized placebo-controlled trial. BMC Mu — View Citation

Wu C, Tan C, Wang L. Higher doses of topical tranexamic acid safely improves immediate functional outcomes and reduces transfusion requirement in total knee arthroplasty. Arch Orthop Trauma Surg. 2020 Dec;140(12):2071-2075. doi: 10.1007/s00402-020-03591-4 — View Citation

* Note: There are 13 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Incidence of treatment-emergent adverse event	monitoring for safety events	postoperative day 3
Other	Incidence of treatment-emergent adverse event	monitoring for safety events	postoperative week 2
Other	Incidence of treatment-emergent adverse event	monitoring for safety events	postoperative week 6
Other	Incidence of treatment-emergent adverse event	monitoring for safety events	postoperative week 12
Primary	Hemoglobin level	Hemoglobin enables red cells to transport oxygen and carbon dioxide in the blood and is measured in grams per deciliter with normal ranges of 12.0 to 17.5	preoperative
Primary	Hemoglobin level	Hemoglobin enables red cells to transport oxygen and carbon dioxide in the blood and is measured in grams per deciliter with normal ranges of 12.0 to 17.5	postoperative hour 3
Primary	Hemoglobin level	Hemoglobin enables red cells to transport oxygen and carbon dioxide in the blood and is measured in grams per deciliter with normal ranges of 12.0 to 17.5	postoperative day 3
Primary	Hemoglobin level	Hemoglobin enables red cells to transport oxygen and carbon dioxide in the blood and is measured in grams per deciliter with normal ranges of 12.0 to 17.5	postoperative week 2
Secondary	Visual Analog Score	Patient reported pain score from 0 to 10 where 0 is no pain and 10 is the most pain	preoperative
Secondary	Visual Analog Score	Patient reported pain score from 0 to 10 where 0 is no pain and 10 is the most pain	postoperative hour 3
Secondary	Visual Analog Score	Patient reported pain score from 0 to 10 where 0 is no pain and 10 is the most pain	postoperative week 2
Secondary	Visual Analog Score	Patient reported pain score from 0 to 10 where 0 is no pain and 10 is the most pain	postoperative week 6
Secondary	Visual Analog Score	Patient reported pain score from 0 to 10 where 0 is no pain and 10 is the most pain	postoperative week 12
Secondary	KOOS Jr Score	Patient reported outcome of how the knee feels from 0 to one 100 where 0 represents extreme problems and 100 represents no problems	preoperative
Secondary	KOOS Jr Score	Patient reported outcome of how the knee feels from 0 to one 100 where 0 represents extreme problems and 100 represents no problems	postoperative day 3
Secondary	KOOS Jr Score	Patient reported outcome of how the knee feels from 0 to one 100 where 0 represents extreme problems and 100 represents no problems	postoperative week 2
Secondary	KOOS Jr Score	Patient reported outcome of how the knee feels from 0 to one 100 where 0 represents extreme problems and 100 represents no problems	postoperative week 6
Secondary	KOOS Jr Score	Patient reported outcome of how the knee feels from 0 to one 100 where 0 represents extreme problems and 100 represents no problems	postoperative week 12
Secondary	KOOS Jr Score	Patient reported outcome of how the knee feels from 0 to one 100 where 0 represents extreme problems and 100 represents no problems	postoperative one year
Secondary	range of motion of knee	clinical measurement of passive, pain-free range of motion of knee in degrees from 0 to 180 from maximum extension to maximum flexion	preoperative
Secondary	range of motion of knee	clinical measurement of passive, pain-free range of motion of knee in degrees from 0 to 180 from maximum extension to maximum flexion	postoperative day 3
Secondary	range of motion of knee	clinical measurement of passive, pain-free range of motion of knee in degrees from 0 to 180 from maximum extension to maximum flexion	postoperative week 2
Secondary	range of motion of knee	clinical measurement of passive, pain-free range of motion of knee in degrees from 0 to 180 from maximum extension to maximum flexion	postoperative week 6
Secondary	range of motion of knee	clinical measurement of passive, pain-free range of motion of knee in degrees from 0 to 180 from maximum extension to maximum flexion	postoperative week 12